Karim Lotfy Mohammed, MD
Psychiatry · San Diego, CANPI 1558657676
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 46.4% of the total. Reporting peaked in 2019 at $359 and has fallen 86.7% since, to $48 in 2021.
Across 33 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$256
- Otsuka America Pharmaceutical, Inc.$125
- Johnson & Johnson$56
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$32
- Shire North American Group Inc$21
- Takeda Pharmaceuticals U.S.A., Inc.$20
- plus $42 from 3 others
What the payments were for
- Food & beverage$551100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $256 |
| Otsuka America Pharmaceutical, Inc. | 7 | $125 |
| Johnson & Johnson | 2 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Shire North American Group Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Lundbeck LLC | 1 | $11 |
How this compares
$551 in reported general payments places this provider in the 65th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 11 | $10,215 |
| Trazodone Hcl | 19 | $359 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in San Diego
- Jonathan MeyerSan Diego$2.3M
- Sanjai RaoSan Diego$445K
- Murray SteinSan Diego$121K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.